TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27633250
Drug: Sembragiline (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sembragiline (lower doses)
Study: 21733214
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (MPH) 18, 36 or 72 mg/day
Study: 21673083
Drug: Osteopathic Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manual Therapy (OMT) protocol consisting of myofascial release of the thoracic inlet, pectoral traction, rib raising, thoracic pump, and abdominal pump for 15 minutes.
Study: 10229464
Drug: Control (observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (observation without treatment)
Study: 23363713
Drug: Adding folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding folic acid 5 mg/day and vitamin B(12) 500 µg twice daily (Group 2)
Study: 23363713
Drug: Adding folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding folic acid 5 mg/day, vitamin B(12) 500 µg twice daily and probucol 500 mg twice daily (Group 3)
Study: 23363713
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive medication (Group 1)
Study: 20868458
Drug: risperidone (0.5‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (0.5‐2 mg/day)
Study: 20868458
Drug: divalproex (60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: divalproex (60‐120 μg/mL)
Study: 11829701
Drug: eptifibatide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: eptifibatide (two 180‐microg/kg boluses, 10 minutes apart, with a continuous infusion of 2.0 microg/kg per minute; n = 1040)
Study: 10350964
Drug: Standard services
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard services (treatment-as-usual, TAU)
Study: 7287240
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg methyldopa (or 500 mg if poor response)
Study: 31648455
Drug: Analgesic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic mixture of morphine, ropivacaine, epinephrine, ketorolac and betamethasone
Study: 27720602
Drug: epinastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinastine 0.05% ophthalmic solution
Study: 22963378
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (in- and outpatient) including strength, flexibility, and aerobic exercise, performed 5 times/week during hospitalization and a combination of supervised and home-based sessions using the Wii device for 10 weeks after discharge.
Study: 15305311
Drug: GBE-NT (discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBE-NT (discontinuation group)
Study: 15305311
Drug: NT-GBE (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-GBE (new treatment group)
Study: 15305311
Drug: NT-NT (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-NT (no treatment group)
Study: 9512274
Drug: Prior radiation
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior radiation and/or chemotherapy
Study: 8062521
Drug: rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapeseed oil mayonnaise with a small dose of sitostanol ester (800 mg/day of sitostanol)
Study: 8062521
Drug: rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapeseed oil mayonnaise with a higher dose of sitostanol ester (2000 mg/day of sitostanol)
Study: 3173998
Drug: 10 IU/cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 IU/cc heparin infusion
Study: 3173998
Drug: 5 IU/cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU/cc heparin infusion
Study: 22512264
Drug: Vildagliptin +
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin + Metformin
Study: 18172697
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) added to general practitioners' care
Study: 8222658
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing gestodene
Study: 8222658
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing norethindrone
Study: 30125457
Drug: Marine n‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n‐3 fatty acids (2.6 g daily for 44 weeks)
Study: 23351923
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (CO)
Study: 19287306
Drug: GSH 1500
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSH 1500 mg/m before oxaliplatin infusion
Study: 19287306
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution before oxaliplatin infusion (Control)
Study: 11812711
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injection with 8 mL of 0.125% bupivacaine and 40 mg of methylprednisolone (20 mg/mL) at a rate of 6 mL/min.
Study: 11812711
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion pressure measurement in DSD patients before treatment.
Study: 7555530
Drug: Enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (mean daily dose 35 +/- 11.4 mg)
Study: 7555530
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean daily dose 50 +/- 12.9 mg)
Study: 7371971
Drug: Paper Pill
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper Pill (30 microgram ethinyloestradiol and 150 microgram levonorgestrel)
Study: 7371971
Drug: Microgynon 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon 30 (conventional tablet formulation)
Study: 28844318
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet (1 to 24 development units, DU)
Study: 28844318
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet (12 and 24 DU)
Study: 24047236
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program (Staff as Change Agents - Enhancing and Sustaining Mental Health in Aged Care)
Study: 16553019
Drug: Tiagabine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 6 mg
Study: 17557435
Drug: Tiagabine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 10 mg
Study: 15058157
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine premedication (0.15 mg)
Study: 15058157
Drug: Intramuscular clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular clonidine premedication (0.15 mg)
Study: 15058157
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral or intramuscular)
Study: 15058157
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intramuscular clonidine
Study: 15058157
Drug: Intramuscular clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular clonidine
Study: 11011346
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/d for 8 weeks
Study: 11011346
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/d plus Enalapril 5 mg/d for 8 weeks
Study: 11011346
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/d for 8 weeks
Study: 11011346
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/d plus Simvastatin 10 mg/d for 8 weeks
Study: 8800119
Drug: 450 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/day oral propafenone (Group 1)
Study: 31594876
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg daily for 1 month, followed by 80 mg daily for 23 months)
Study: 24261227
Drug: Adaptol 1500-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptol 1500-2000 mg/day for 30+2 days
Study: 18392690
Drug: pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (30 mg/day; n = 14)
Study: 18392690
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/day; n = 11)
Study: 18392690
Drug: placebo (medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (medical nutrition therapy; n = 10)
Study: 12837435
Drug: tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tadalafil 20 mg
Study: 10440425
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg once daily for 7 days
Study: 12396958
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 7 days
Study: 10440425
Drug: Nifedipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (calcium uptake antagonist)
Study: 8646251
Drug: dexfenfluramine (dF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexfenfluramine (dF) 30 mg/day
Study: 1349486
Drug: sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release verapamil 200 mg b.i.d.
Study: 1349486
Drug: conventional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional verapamil 120 mg t.i.d.
Study: 3972657
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate radiotherapy
Study: 3972657
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated irradiation at normal high dose rate
Study: 31181022
Drug: EMLA patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA patch (standard care)
Study: 20393347
Drug: Extended buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended buprenorphine/naloxone therapy (BUP) for 12 weeks
Study: 18350637
Drug: Esomeprazole enteric-coated
Normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole enteric-coated capsules (40 mg)
Study: 18350637
Drug: Esomeprazole magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole magnesium (40 mg)
Study: 12075272
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (6 1-g capsules providing 3 g eicosapentaenoic acid and 2.1 g docosahexaenoic acid/d)
Study: 29603547
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (CGM and standard treatment)
Study: 18446021
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ascorbic acid and 400 IU of alpha-tocopherol for 6 months
Study: 18446021
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of ascorbic acid and 400 IU of alpha-tocopherol for 6 months
Study: 12881451
Drug: Xuezhikang (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (1200 mg daily)
Study: 11254068
Drug: Home-based multisystemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based multisystemic therapy (MST)
Study: 30550982
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplements (16 weeks)
Study: 26312616
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min of the Stroop task (mentally fatiguing treatment)
Study: 26312616
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min of reading magazines (control treatment)
Study: 22261578
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) supplementation (1.7 g of cis-9,trans-11 and trans-10,cis-12 CLA in 200 mL of sterilized milk twice daily for 12 weeks)
Study: 22261578
Drug: Placebo (salad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (salad oil in 200 mL of sterilized milk twice daily for 12 weeks)
Study: 17484381
Drug: Test food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test food (40 mg of soy isoflavone aglycone per day)
Study: 11932472
Drug: Sulindac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (75 or 150 mg orally twice a day for 48 months)
Study: 11932472
Drug: Placebo (identical-appearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-appearing tablets for 48 months)
Study: 9751323
Drug: Mitoxantrone in
Normalized name: Mitoxantrone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone in combination with steroids
Study: 9751323
Drug: Secondary hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secondary hormonal therapies (alternative antiandrogens and anti‐adrenal agents)
Study: 9751323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prostate specific antigen values with quality of life and measurable disease responses
Study: 7790732
Drug: Indomethacin pretreatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin pretreatment (50 mg suppository administered 30 min before hyperthermia)
Study: 1722918
Drug: Org 10172
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 10172 (Lomoparan, i.v. bolus injection of 3,250 anti‐Xa units followed by 750 units twice daily s.c. for 8 days)
Study: 1722918
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (500 mg orally 14 and 2 h before i.v. Org 10172 administration)
Study: 7152443
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose uricostatic and uricosuric regimen
Study: 25915826
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of one portion of cake fortified with barley's beta‐glucan
Study: 25915826
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of the same cake without the enrichment (placebo)
Study: 9854508
Drug: EET therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EET therapy (intravenous administration of IFN‐gamma or TNF‐SAM2 followed by OK‐432)
Study: 9854508
Drug: EET therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EET therapy (more than 5 courses)
Study: 9854508
Drug: EET therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EET therapy
Study: 2212408
Drug: Inhaled adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled adenosine 5'-monophosphate (AMP)
Study: 26349123
Drug: Experimental dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental dentifrice formulations (1450 ppm fluoride) with 2% isopentane
Study: 26349123
Drug: Experimental dentifrice
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental dentifrice formulations (1450 ppm fluoride) without 2% isopentane
Study: 10720518
Drug: Thalidomide therapy
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide therapy
Study: 19883313
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of T cell expansions (regardless of therapy)
Study: 15112860
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (10 mg i.v.)
Study: 11552902
Drug: Ridogrel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridogrel (5 mg/day for 12 weeks)
Study: 9631813
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler (MDI) delivering 100 microg of methacholine
Study: 7697689
Drug: Sustained-release cream
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release cream
Study: 7697689
Drug: Standard cream
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard cream
Study: 3666661
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg orally)
Study: 31922999
Drug: Midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.04 mg·kg)
Study: 29433481
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus early ACLR
Study: 29433481
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus delayed ACLR
Study: 25515553
Drug: Botanical oil
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Botanical oil (BO) combination (borage/echium oil)
Study: 22901969
Drug: Bivalirudin (BIV)
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivalirudin (BIV) + 2-hour infusion after PCI
Study: 22901969
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa receptor inhibitor (GPI)
Study: 18761239
Drug: Superficial cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial cervical plexus block with 0.35 mL/kg of 0.5% levobupivacaine
Study: 18761239
Drug: Combined cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cervical plexus block with 0.2 mL/kg of 0.5% levobupivacaine (deep) and 0.15 mL/kg (superficial)
Study: 11821603
Drug: Ropivacaine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 200 mg dissolved in 100 ml saline
Study: 11821603
Drug: Saline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 100 mg
Study: 10765864
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (n = 24): Irreversibly infected dentin was partially removed prior to the application of the bonding agent and restorative material.
Study: 10765864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 24): All identifiable, irreversibly infected dentin was removed prior to the application of the bonding agent and restorative material.
Study: 7669483
Drug: Isoprenaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (10 min i.v. infusion of 1 microgram min-1)
Study: 7669483
Drug: Adrenaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (10 min i.v. infusion of 1 microgram min-1)
Study: 7669483
Drug: Isomazole (p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomazole (p.o. administration of 40 mg)
Study: 7669483
Drug: Meribendan (p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meribendan (p.o. administration of 40 mg)
Study: 7669483
Drug: Celiprolol (p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (p.o. administration of 1200 mg)
Study: 2285629
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 x 10 mg capsules three times daily)
Study: 2285629
Drug: Nisoldipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (2 x 10 mg tablets once daily)
Study: 7023715
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 1.5 mg/kg on day 1 + ARA‐C 2 mg/kg on days 1‐5 (R1)
Study: 7023715
Drug: Daunorubicin (DNR)
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin (DNR) 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R2)
Study: 7023715
Drug: Daunorubicin-DNA complex
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin-DNA complex 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R3)
Study: 7023715
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with DNR-DNA complex vs free DNR
Study: 31862174
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (SBP goal of <120 mmHg)
Study: 31862174
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (SBP goal of <140 mmHg)
Study: 25729623
Drug: Ciclesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (200 µg)
Study: 23816671
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg 2 h prior to induction of anesthesia and 75 mg twice daily for 2 post-operative days
Study: 17426398
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel + fluoridated dentifrice
Study: 22037722
Drug: Topical suspension
Normalized name: Topical Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical suspension of bacterial antigens (Lantigen B)
Study: 11176083
Drug: Remifentanil (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (loading dose 1 microg/kg; maintenance infusion, 0.25 microg x kg(‐1) x min‐1)
Study: 11176083
Drug: Alfentanil (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (loading dose, 50 microg/kg; maintenance infusion, 1 microg x kg(‐1) x min‐1)